Lamotrigine-induced common variable immune deficiency

Neurology

Volumn 62, Issue 5, 2004, Pages 833-834

  Smith, Julie ^a   Fernando, Tus ^b   McGrath, Nicole ^b   Ameratunga, Rowan ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b WHANGAREI HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE COURSE; DOSE RESPONSE; EPILEPSY; FATIGUE; HALLUCINATION; HUMAN; HYPOGAMMAGLOBULINEMIA; MALE; NAUSEA; PRIORITY JOURNAL; RASH; TREATMENT PLANNING;

EID: 1542376017     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000113754.29225.5D     Document Type: Article

References (6)

1. Basaran N, Hincal F, Kansu E, Ciger A. Humoral and cellular immune parameters in untreated and phenytoin or carbamazepine treated epileptic patients. Int J Immunopharmacol 1994;16:1071-1077.
2. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-1400.
3. Sabers A, Gram L. Newer anticonvulsants. Comparative review of drug interactions and adverse effects. Drugs 2000;60:23-33.
4. Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:281-296.
5. Bonilla FA. Combined B and T cell deficiencies. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical and Laboratory Immunology, 6th ed. Washington DC: ASM Press, 2002.
6. Travin M, Macris NT, Block JM, Schwimmer D. Reversible common variable immunodeficiency syndrome induced by phenytoin. Arch Intern Med 1989;149:1421-1422.